Literature DB >> 31924724

Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?

Susanne Lütje1, Georg Feldmann2, Markus Essler3, Peter Brossart2, Ralph A Bundschuh3.   

Abstract

Immune checkpoint blockade represents a promising approach in oncology, showing antitumor activities in various cancers. However, although being generally far better tolerated than classic cytotoxic chemotherapy, this treatment, too, may be accompanied by considerable side effects and not all patients benefit equally. Therefore, careful patient selection and monitoring of the treatment response is mandatory. At present, checkpoint-specific molecular imaging is being increasingly investigated as a tool for patient selection and response evaluation. Here, an overview of the current developments in immune checkpoint imaging is provided.
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  PET/CT; checkpoint blockade; molecular imaging; oncology

Mesh:

Year:  2020        PMID: 31924724      PMCID: PMC7413235          DOI: 10.2967/jnumed.119.237891

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  80 in total

1.  PD-L1 expression as a potential predictive biomarker.

Authors:  Alberto Fusi; Lucia Festino; Gerado Botti; Giuseppe Masucci; Ignacio Melero; Paul Lorigan; Paolo A Ascierto
Journal:  Lancet Oncol       Date:  2015-10       Impact factor: 41.316

2.  Correction to: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.

Authors:  Rudolf A Werner; Harun Ilhan; Sebastian Lehner; László Papp; Norbert Zsótér; Imke Schatka; Dirk O Muegge; Mehrbod S Javadi; Takahiro Higuchi; Andreas K Buck; Peter Bartenstein; Frank Bengel; Markus Essler; Constantin Lapa; Ralph A Bundschuh
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

3.  Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.

Authors:  Dickran Kazandjian; Sean Khozin; Gideon Blumenthal; Lijun Zhang; Shenghui Tang; Meredith Libeg; Paul Kluetz; Rajeshwari Sridhara; Patricia Keegan; Richard Pazdur
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

4.  89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer.

Authors:  Christopher G England; Dawei Jiang; Emily B Ehlerding; Brian T Rekoske; Paul A Ellison; Reinier Hernandez; Todd E Barnhart; Douglas G McNeel; Peng Huang; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-19       Impact factor: 9.236

5.  Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models.

Authors:  Emily B Ehlerding; Hye Jin Lee; Dawei Jiang; Carolina A Ferreira; Christopher D Zahm; Peng Huang; Jonathan W Engle; Douglas G McNeel; Weibo Cai
Journal:  Am J Cancer Res       Date:  2019-01-01       Impact factor: 6.166

6.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

7.  Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.

Authors:  J D Wolchok; J S Weber; M Maio; B Neyns; K Harmankaya; K Chin; L Cykowski; V de Pril; R Humphrey; C Lebbé
Journal:  Ann Oncol       Date:  2013-05-10       Impact factor: 32.976

8.  Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Authors:  Fabrice Barlesi; Johan Vansteenkiste; David Spigel; Hidenobu Ishii; Marina Garassino; Filippo de Marinis; Mustafa Özgüroğlu; Aleksandra Szczesna; Andreas Polychronis; Ruchan Uslu; Maciej Krzakowski; Jong-Seok Lee; Luana Calabrò; Osvaldo Arén Frontera; Barbara Ellers-Lenz; Marcis Bajars; Mary Ruisi; Keunchil Park
Journal:  Lancet Oncol       Date:  2018-09-24       Impact factor: 41.316

Review 9.  Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.

Authors:  Jiabei He; Ying Hu; Mingming Hu; Baolan Li
Journal:  Sci Rep       Date:  2015-08-17       Impact factor: 4.379

10.  Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.

Authors:  Elaine M Jagoda; Olga Vasalatiy; Falguni Basuli; Ana Christina L Opina; Mark R Williams; Karen Wong; Kelly C Lane; Steve Adler; Anita Thein Ton; Lawrence P Szajek; Biying Xu; Donna Butcher; Elijah F Edmondson; Rolf E Swenson; John Greiner; James Gulley; Janet Eary; Peter L Choyke
Journal:  Mol Imaging       Date:  2019 Jan-Dec       Impact factor: 4.488

View more
  3 in total

1.  High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.

Authors:  Rudolf A Werner; Thorsten Derlin; Steven P Rowe; Lena Bundschuh; Gabriel T Sheikh; Martin G Pomper; Sebastian Schulz; Takahiro Higuchi; Andreas K Buck; Frank M Bengel; Ralph A Bundschuh; Constantin Lapa
Journal:  J Nucl Med       Date:  2020-08-28       Impact factor: 10.057

2.  ImmunoPET of CD38 with a radiolabeled nanobody: promising for clinical translation.

Authors:  Sixiang Shi; Shreya Goel; Xiaoli Lan; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08       Impact factor: 10.057

3.  Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.

Authors:  Alexander Rühle; Anca-L Grosu; Nicole Wiedenmann; Michael Mix; Raluca Stoian; Gabriele Niedermann; Dimos Baltas; Martin Werner; Wolfgang A Weber; Gian Kayser; Nils H Nicolay
Journal:  Theranostics       Date:  2020-07-23       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.